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Abstract 
Objectives:  To compare clinical characteristics of menstrual and non-menstrual attacks of migraine 
without aura (MO), prospectively recorded in a headache diary, by women with and without a 
diagnosis of menstrual migraine without aura (MM) according to the International Classification of 
Headache Disorders (ICHD). 
Material and methods: 237 women from the general population with self-reported migraine in ≥50% 
of their menstrual periods were interviewed and classified by a physician according to the criteria of 
the ICHD II.  Subsequently, all participants were instructed to complete a prospective headache diary 
for at least three menstrual cycles. Clinical characteristics of menstrual and non-menstrual attacks of 
MO were compared by a regression model for repeated measurements. 
Results: In total, 123 (52%) women completed the diary. In the 56 women who were prospectively 
diagnosed with MM by diary, the menstrual MO-attacks were longer (on average 10.65 hours, 99% CI 
3.17-18.12) and more frequently accompanied by severe nausea (OR 2.14, 99% CI 1.20-3.84) than 
non-menstrual MO-attacks. No significant differences between menstrual and non-menstrual MO-
attacks were found among women with MO, but no MM.  
 
Conclusion: In women from the general population, menstrual MO-attacks differ from non-
menstrual attacks only in women who fulfil the ICHD criteria for MM. 
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Introduction 
About 20 % of female migraineurs from the general population suffer from menstrual migraine 
without aura (MM)(1, 2), defined as attacks of migraine without aura (MO) occurring on day 1±2 (i.e. 
days -2 to +3) of menstruation in at least two out of three menstrual cycles (3). MM is subdivided 
into pure menstrual migraine, including women with attacks of MO exclusively at menstruation, and 
menstrually-related migraine, where attacks also occur at other times of the cycle. The diagnostic 
criteria are placed in the appendix of the International Classification of Headache Disorders (ICHD) II 
and III beta and are primarily considered as research criteria that need further validation before 
possible inclusion into the main body of the classification (3, 4).  
It is debated whether MM is a distinct clinical entity, since previous studies report divergent findings 
concerning differences in characteristics of menstrual and non-menstrual migraine attacks. Analyses 
including women with a diagnosis of MM indicate that menstrual attacks are more painful, longer 
lasting, more disabling and less responsive to treatment (5-9). Most studies reporting that there is no 
difference compare menstrual versus non-menstrual attacks in all women with migraine, without 
considering the required frequency of attacks related to menstruation, and so are likely to include 
women whose menstrual attacks are a chance occurrence rather than there being a true association 
(10-12). Separate and comparative analyses between female migraineurs with and without a 
prospectively confirmed diagnosis of MM have to our knowledge not been published previously. 
The aim of the present study was to compare the clinical characteristics of menstrual and non-
menstrual MO-attacks in women with and without a diary-confirmed diagnosis of MM.  
 
Material and methods 
Screening, population, and clinical interviews 
A random sample of 5000 women, aged 30-34 years, from the general population received a mailed 
screening questionnaire about headache, migraine and its relation to menstruation. The response 
rate to the questionnaire was 73%. Women with self-reported migraine in ≥50% of their 
menstruations and < 180 headache days during the preceding year were invited to a clinical 
interview and examination conducted by a headache specialist (KGV). At interview time the 
participants were 36-40 years old. Of 360 women meeting the inclusion criteria, 52 were not eligible 
due to emigration (n=4), insufficient Norwegian language skills (n=9), and no reply to five telephone 
calls or more (n=39). Among the 308 eligible women, 237 (77%) participated in the interview. 
Seventy-one declined to participate due to lack of time, no interest, or acute illness. Women, who 
were not able to come to the clinic, were interviewed by telephone (87/237). The interview focused 
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on headache diagnoses and characteristics. Subsequently all women were asked to complete a 
prospective headache- and menstruation paper-pencil diary for three months. A more exhaustive 
description of the screening method and interviews is published elsewhere (1, 13). 
When a headache occurred, the women recorded: time of onset and end of headache, aura 
symptoms, pain quality and location, severity on Numeric Rating Scale 0-10 (NRS; 0=no pain, 10= 
most severe pain), aggravation by routine physical activity, medical treatment (type and dose) and 
sick leave. The associated symptoms (i.e. nausea, photo- and phonophobia) were graded 0-3; 0=no 
symptoms, 1=mild, 2=moderate and 3=severe. In addition, women were asked to record each day of 
uterine bleeding.  
The women were allowed to take their usual medication including migraine prophylaxis and 
hormonal contraception. The diaries were returned by mail in a stamped pre-addressed envelope. If 
a diary was not returned after three months, one reminder was issued.  
 
Data entry and analysis of headache diaries  
The diaries were reviewed by two investigators (KGV and MBR) and the diary database was 
constructed by one investigator (KGV) in order to ensure consistency. In cases with missing 
information about the exact timing of menstruation, the subject was contacted by telephone to 
elaborate the information. When a migraine attack lasted more than one day, it was considered as a 
single multiday attack, unless an interval of ≥48 hours pain-free separated the headaches. This 
definition was used since most of the attacks were treated with symptomatic drugs and migraine 
occurring within 48 hours is considered as relapse of migraine in randomized controlled drug trials 
(14). When all but one ICHD criterion for MO were fulfilled, or the duration was <4 hours, the attack 
was considered as MO if symptomatic treatment was used. A diagnosis of MM required at least two 
MO attacks with onset on day 1±2 of the menstrual cycle during three consecutive cycles. If an attack 
started outside the defined period (day 1±2), it was considered as a non-menstrual attack.  In order 
to make comparisons between the same headache types, i.e. MO, attacks of migraine with aura and 
tension-type headache were excluded. Status migrainosus was defined as  debilitating attacks lasting 
for more than 72 hours with remissions up to 12 hours because of medication or sleep (3). 
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Statistics 
Continuous demographic and clinical characteristics were presented as means and standard 
deviations (SDs), while frequencies and percentages were used to describe dichotomous 
characteristics. Independent samples t-test or Fisher’s exact test was used to compare the 
characteristics between women with and without MM. Three continuous (pain score, duration and 
number of doses), three graded categorical (nausea, photo-and phonophobia) and two dichotomous 
(treatment and sick leave) parameters were recorded for each migraine attack, resulting in repeated 
measurements for each woman. Differences in menstrual and non-menstrual migraine attacks were 
assessed by a regression model for repeated measurements adjusting for intra-individual 
correlations; linear for continuous, ordinal for categorical and logistic for dichotomous parameters. 
Intra-class correlation coefficient (ICC) was calculated to assess the proportion of variance occurring 
within-women. Regression models contained fixed effect for variable categorizing the attacks into 
menstrual and non-menstrual attacks in women with and without a diagnosis of MM, with non-
menstrual attacks in women with a diagnosis of MM as reference category. Random effect for 
intercept, accounting for within-woman variability, was included into the model. Results were 
presented as coefficients or odds ratios (ORs) with 99% confidence intervals (CIs). The coefficient 
from a linear model represents estimated average difference between the reference and three other 
categories (i.e. menstrual and non-menstrual attacks in women without MM and menstrual attacks 
in women with MM). Ordinal and logistic regression models estimate the odds for presence of a 
specific symptom in a certain category with respect to the reference category. The ratio of the 
generalized χ2 statistic and its degrees of freedom was nearly one in the logistic models indicating no 
overdispersion in the data. Baseline factors differing between the groups (migraine days/cycle, 
migraine attacks/cycle and employment status) were included into the models with significant 
associations one at a time to test if the associations were modified. In addition, the models were 
adjusted for progestin-only and combined hormonal contraception. None of the associations were 
affected by these adjustments. 
All analyses were performed in SPSS v20 and SAS v9.3 (MIXED and GLIMMIX procedures). A 
significance level of 0.01 was chosen to partially address for multiple tests. 
Ethics 
The study was approved by the Regional Committee for Medical Research Ethics and the Norwegian 
Data Protection Authorities. The participants received written and verbal information about the 
project and inclusion was based on informed consent. No reimbursement for participation was given. 
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Results 
Among the 237 women who were interviewed, 123 (52%) returned the diary. Of these, 42 were 
excluded from analysis due to oligo-/amenorrhoea (n=36), exclusively tension-type headache (n=4) 
or incomplete diaries (n=2). Thus, diaries from 81 women were analysed (figure 1). Women who 
were interviewed face-to-face, were significantly more likely to return the diary compared to those 
interviewed by telephone (OR=2.87, 95% CI 1.66-4.96). There were no significant differences 
between women who returned and those who did not return the diary with respect to clinical MM-
diagnosis or migraine frequency (13). 
A total of 56 women fulfilled the diagnostic criteria for MM in the diary, while 25 women had MO, 
but did not fulfil the criteria for MM. The 81 women recorded a total of 261 menstrual cycles and 435 
MO-attacks (908 MO-days) during the 7202 diary-days. Women with MM recorded 167 menstrual 
and 191 non-menstrual MO-attacks, while the respective numbers in women without MM were 19 
and 58. Mean menstrual cycle length in all 81 women was 28.4± 4.5 days, with no difference 
between the groups. 
Demographic and clinical characteristics of women with and without MM 
Table 1 shows demographic and clinical characteristics of women with and without a diary-confirmed 
diagnosis of MM. Women with MM had a higher migraine frequency recording on average 2.0 
migraine attacks per cycle, compared to 1.4 in women without MM (P=0.006). There were no 
differences between women with and without MM with respect to age at menarche or migraine 
onset, use of hormonal contraception or migraine prophylaxis, self-reported menstrual pain or a 
diagnosis of endometriosis.  The levonorgestrel-Intrauterine system was the most frequently used 
progestin-only contraception, used by seven women with MM and one woman without MM. One 
woman in each group used the Desogestrel-only pill. Among users of combined hormonal 
contraception, one woman (with MM) used the vaginal ring, while the remaining used the combined 
contraceptive pill. All women used the combined hormonal contraceptives in a cyclic regimen. The 
proportions of users of the subtypes of contraception did not differ between women with and 
without MM (table 1). 
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Characteristics of menstrual and non-menstrual MO-attacks  
Clinical characteristics of menstrual and non-menstrual MO-attacks in women with and without a 
diary-diagnosis of MM are presented in Table 2. Intra-class correlation (ICC) was varying between 
25% and 52%, demonstrating a considerable variation of MO-attacks from time to time within the 
same individual. 
Women with a diary diagnosis of MM  
Menstrual MO-attacks lasted significantly longer than non-menstrual attacks and were more often 
accompanied by severe nausea in women with MM (table 2).  A non-significant trend towards more 
occurrence of status migrainosus was observed (OR 4.34, 99% CI 0.94-20.09) and the menstrual 
attacks tended to be more painful (0.37 on a 0-10 score, 99% CI -0.08-0.81). No difference in sick 
leave was observed between the menstrual and non-menstrual attacks (OR 1.41, 99% CI 0.55- 3.58). 
Menstrual migraine attacks were treated with significantly more doses of symptomatic drugs per 
attack and multiple agent treatment strategies were more often recorded (Table 3). The proportion 
of attacks treated with triptans did not differ between menstrual and non-menstrual attacks (table 
3), but the number of triptan doses per attack was significantly higher in the menstrual attacks (mean 
difference 1.37, 99% CI 0.50-2.24). A non-significant trend towards more use of NSAIDs was 
additionally observed in the menstrual attacks (table 3).  
Women with MO, without a diary diagnosis of MM 
The confidence intervals indicate that there were no significant clinical differences between 
menstrual and non-menstrual attacks in women not fulfilling the criteria for MM (Table 2). Nor did 
treatment differ between menstrual and non-menstrual attacks in this group (table 3).  
Additional analyses using other diagnostic methods 
We also performed the analyses on women classified according to their interview-diagnosis of MM 
(n=81), disregarding the diary-diagnoses. Additionally we performed a third analysis including only 
women with the same MM-diagnosis according to both interview and diaries (n=66). In both 
analyses, the menstrual attacks remained significantly longer, required more doses of symptomatic 
treatment and were more often associated with nausea. There were no differences in characteristics 
of the menstrual attacks between the women with pure menstrual migraine and menstrually-related 
migraine. 
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Discussion 
Our main finding is that menstrual attacks of MO are significantly longer and more often associated 
with severe nausea than non-menstrual attacks in women who fulfil the ICHD-criteria for MM. We 
found no differences between menstrual and non-menstrual attacks in women with MO, but no 
diary-confirmed diagnosis of MM.   
Our results may thus explain the divergent findings between previous studies, as the differences 
most likely depend on the women’s diagnosis of MM. Among the previous diary-studies, only four 
compare characteristics of menstrual and non-menstrual attacks in women with a diagnosis of MM 
(5-8). These studies consistently find that menstrual attacks are more disabling, longer lasting, and 
more difficult to treat, while the results concerning pain intensity and associated symptoms are 
conflicting. We observed a non-significant trend towards more painful attacks, but the magnitude of 
difference was small and probably not clinically relevant, i.e. 0.37 on a 0-11 point scale.  Among the  
studies comparing menstrual and non-menstrual attacks among all female migraineurs, without 
restricting their sample to women diagnosed with MM, the results vary from no difference to similar 
results as ours (10-12). In two of these studies, the proportions of menstrual attacks of all migraine 
attacks were 19% and 23% (11, 12). In our population of women with MM and in a previous study of 
women with MM (8), menstrual attacks represented 47% (167/358) and 59% of all migraine attacks. 
This may indicate that some of the studies of all female migraineurs included few women with a 
diagnosis of MM.  
Several randomized controlled trials (RCT) and post hoc analyses of RCTs report that triptans are 
superior to placebo in the acute treatment of menstrual migraine attacks, both in women with and 
without a confirmed diagnosis of MM (11, 15, 16). However, when responses to treatment are 
compared between menstrual and non-menstrual attacks in women diagnosed with MM,  significant 
lower 2-h pain-free responses and higher recurrence rates within 24 hours in menstrual attacks are 
reported (5, 6, 8). Our study was not designed to evaluate treatment efficacy, but the fact that the 
menstrual attacks were on average nearly 11 hours longer and required more doses of triptans, may 
indicate a higher relapse rate and/or lower efficacy of the initial dose in the menstrual attacks of 
women with MM. In addition we observed a non-significant trend towards more use of NSAIDs or 
multiple-agent strategies in the menstrual attacks, which could be explained by the general 
knowledge that NSAIDs are effective against comorbid menstrual pain. However, according to our 
interview data, women with MM reported modest menstrual pain (on average 3.4 on a -10 point 
scale) and there were no significant differences among women with and without the MM-diagnosis 
(Table 1). Since the menstrual attacks in women with MM were treated with more symptomatic 
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drugs, the real clinical differences between the attacks may be even more marked than our results 
suggest.  
Strengths and limitations  
This is the first study from the general population comparing menstrual and non-menstrual attacks in 
women with a diagnosis of MM using a headache- and menstruation diary. The previous studies were 
conducted in clinic populations and questions have been raised concerning the possible influence of 
selection bias (10). Our study is, to our knowledge, the first study which assesses attacks in female 
migraineurs with and without a diagnosis of MM. The women recorded on average 3.2 menstrual 
cycles, which is required in order to establish the diagnosis. Several of the previous studies only 
included 1-2 cycles. Moreover, none of the participants in our study had chronic migraine. Studies 
including women with very frequent migraine are more likely to include women with menstrual 
attacks by chance. We excluded migraine with aura attacks, since the headache following migraine 
aura does not necessarily have pain and accompanying symptoms similar to that of MO  (2, 17, 18).  
Our statistical methods used to assess the differences between the attacks adjust the estimates for 
correlations due to repeated measures. In addition, the methods used minimize effects of missing 
data by including all available information into the model. Due to multiple tests, we also chose a 
conservative significance level (<0.01) to reduce the risk of mass significance by chance.  
Only 52% of the participants returned the diary, which might introduce a bias in our results. 
However, there were no difference between women who returned the diary and those who did not 
regarding migraine diagnoses, migraine frequency, educational level or income. The only difference 
noticed, was the higher return rate of diaries among women who were interviewed face-to-face 
compared to those interviewed by telephone. This might indicate that women who invested time in 
order to come to the hospital for a face-to-face interview were more motivated and interested in 
participation.  
All women in this study were invited to the initial clinical interview based on their self-report of 
migraine in at least half of menstruations six years previously. Thus, the 25 women who were not 
diagnosed with MM by diary are not representative for all female migraineurs due to the self-
reported association between migraine and menstruation. The six years delay between screening 
and interview did not influence the presented results, since we only analysed data from diaries and 
interviews that were collected in close temporal relation. Since we restricted inclusion to women 
aged 36-40 years our results may not be representative of older or younger women. 
In our sample, we could not identify differences between menstrual and non-menstrual attacks in 
the 25 women with MO attacks, but no MM. Their attacks represented less than one fifth of all MO-
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attacks analysed and we cannot exclude the possibility that the analyses of the women without MM 
lacked statistical power. The differences observed between women with and without MM should 
however be considered in future studies of MM, and stresses the importance of separate analyses of 
the two groups.  
The use of migraine prophylaxis or hormonal contraception could have influenced on our results, but 
the proportion of users was equally distributed between the groups.  
Conclusion 
In women from the general population who fulfil the ICHD criteria for MM, menstrual MO- attacks 
are longer lasting, and more often associated with severe nausea than non-menstrual attacks. 
However, in women with migraine, but no MM, menstrual attacks do not differ significantly from 
non-menstrual migraine attacks.  
Funding 
This study was supported by grants from the South-Eastern Norway Regional Health Authority (grant 
number 2013001), Akershus University Hospital (grant number 2629014) and Institute of Clinical 
Medicine, University of Oslo. 
Conflict of Interest Statement 
None declared 
Clinical implications 
x In women with a diagnosis of menstrual migraine without aura, menstrual attacks were 
longer lasting, more often associated with nausea, and treated with more doses of 
symptomatic drugs than non-menstrual migraine attacks. 
x In women with migraine without aura, not fulfilling the diagnostic criteria for menstrual 
migraine, no differences between menstrual and non-menstrual attack were found. 
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Table and figures 
Figure 1. Flow chart of the study 
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Table 1. Demographic and clinical characteristics of the participants 
 MM- 
diagnosis  
(n=56) 
No MM-
diagnosis 
(n=25) 
p-value 
 
Continuous variables 1 Mean (SD)  
Age (years) 38.3 (1.3) 38.6 (1.3) 0.35 
Age at migraine onset (years)  19.0 (7.5) 21.0 (7.1) 0.27 
Age at menarche (years)  12.9 (1.4) 13.1 (1.8) 0.58 
Cycle length (days)  28.5 (5.0) 28.2 (3.4) 0.71 
Migraine days/cycle 4.4 (2.5) 2.7 (2.3) 0.007 
Migraine attacks/cycle 2.0 (0.9) 1.4 (1.0) 0.006 
Menstrual pain (0-10)  3.4 (2.5) 3.1 (2.9) 0.71 
Dichotomous variables 2 % (n)  
Migraine prophylaxis  8.9 (5) 0 (0) 0.32 
Hormonal contraception  
Combined hormonal contraception 
Progestin-only contraception 
26.8 (15) 
12.5 (7) 
14.3 (8) 
24.0 (6) 
16.0 (4) 
8.0 (2) 
1.00 
0.73 
0.72 
Self-reported menorrhagia 23.2 (13) 32.0 (8) 0.42 
Endometriosis 3.6 (2) 8.0 (2) 0.58 
Higher educational level % (n)* 63.6 (35) 62.5 (15) 1.00 
Income >400 000 (NOK/year)** 50.9 (28) 40.9 (9) 0.46 
Employed 91.1 (51) 72.0 (18) 0.04 
Married/living with a partner*** 83.3 (45) 66.7 (16) 0.14 
1Independent t-test. 2Fisher’s exact test. *2 missing values, **4 missing values, ***3 missing 
values. 
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Table 2. Clinical characteristics of menstrual and non-menstrual attacks of migraine without aura 
Diagnosis Continuous variables1 
 
n Mean (SD) Coefficient (99% CI) 
 
Menstrual 
migraine 
 
No menstrual 
migraine 
 
 
Menstrual 
migraine 
 
No menstrual 
migraine 
 
Pain score (0-10) 
   Non-menstrual attack– ref  
   Menstrual attack  
 
   Non-menstrual attack  
   Menstrual attack 
 
Duration of attack (hours) 
   Non-menstrual attack– ref  
   Menstrual attack  
 
   Non-menstrual attack   
   Menstrual attack  
 
 
191 
166 
 
58 
19 
 
 
175 
162 
 
53 
18 
 
 
6.15 (1.85) 
6.49 (1.80) 
 
5.86 (1.88) 
5.68 (1.06) 
 
20.15 (23.98) 
30.39 (32.28) 
 
26.57 (33.55) 
22.28 (25.90) 
 
 
0 
0.37 (-0.08- 0.81) 
 
-0.29 (-1.22- 0.63) 
-0.42 (-1.62-0.79) 
 
 
0 
10.65 (3.17-18.12)* 
 
6.79 (-8.01-21.60) 
3.84 (-15.86-23.54) 
 
Diagnosis Ordinal variables 2 n Severity grade (%)3 OR (99% CI) 
0 1 2 3 
 
Menstrual 
migraine 
 
No menstrual 
migraine 
 
 
Menstrual 
migraine 
 
No menstrual 
migraine 
 
 
Menstrual 
migraine 
 
No menstrual 
migraine 
 
Nausea 
Non-menstrual attack– ref 
Menstrual attack 
 
Non-menstrual attack 
Menstrual attack 
 
Photophobia 
Non-menstrual attack– ref 
Menstrual attack 
 
Non-menstrual attack 
Menstrual attack 
 
Phonophobia 
Non-menstrual attack– ref 
Menstrual attack 
 
Non-menstrual attack 
Menstrual attack 
 
 
190 
167 
 
57 
19 
 
 
190 
167 
 
55 
18 
 
 
190 
167 
 
52 
18 
 
 
53 
38 
 
47 
47 
 
 
40 
37 
 
33 
50 
 
 
40 
38 
 
55
67 
 
 
27 
34 
 
28 
32 
 
 
35 
30 
 
44 
33 
 
 
37 
31 
 
35
22 
 
 
16 
20 
 
18 
21 
 
 
16 
25 
 
11 
11 
 
 
17 
22 
 
6 
6 
 
4 
8 
 
7 
0 
 
 
9 
8 
 
11 
6 
 
 
6 
9 
 
4 
6 
 
1 
2.14 (1.20-3.84)* 
 
1.75 (0.46-6.68) 
1.58 (0.29-8.51) 
 
 
1 
1.42 (0.77-2.60) 
 
1.81 (0.32-9.35) 
0.81 (0.11-5.90) 
 
 
1 
1.48 (0.79-2.76) 
 
0.35 (0.04-3.15) 
0.80 (0.13-4.70) 
1 Linear mixed model with random intercept (SAS MIXED). 2 Logistic regression for hierarchical data with random 
intercept (SAS GLIMMIX). 3Severity grade %: percentage of women reporting 0= no symptoms, 1=mild, 
2=moderate and 3= severe.  
*p<0.01 
MM=menstrual migraine without aura. n=number of attacks without missing values. SD= standard deviation. 
OR=odds ratio. CI=confidence interval.   
Number of migraine without aura attacks in women with MM: n=167 menstrual and 191 non-menstrual.  
Number of migraine without aura attacks in women without MM: n=19 menstrual and 58 non-menstrual.  
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Table 3. Pharmacological management of migraine without aura 
Diagnosis 
 
Dichotomous variables 1 
 
n % (n) 
 
OR (99% CI) 
 
 Symptomatic treatment used    
Menstrual 
migraine 
Non-menstrual attack– ref  191 85.3 (162) 1 
Menstrual attack  167 92.8 (155) 2.62 (0.91-7.54) 
     
No menstrual 
migraine  
Non-menstrual attack  58 67.2 (39) 0.49 (0.12-2.02) 
Menstrual attack   19 78.9 (15) 0.79 (0.11-5.61) 
     
 Paracetamol    
Menstrual 
migraine 
Non-menstrual attack– ref  191 31.4 (60)  1 
Menstrual attack  167 33.5 (56) 1.41 (0.61-3.26) 
     
No menstrual 
migraine 
Non-menstrual attack  58 48.3 (28)  4.32 (0.90-20.83) 
Menstrual attack   19 63.2 (12) 6.14 (0.84-44.61) 
     
 NSAIDs    
Menstrual 
migraine 
Non-menstrual attack– ref  191 46.1 (88) 1 
Menstrual attack  167 59.3 (99) 2.04 (0.99-4.18) 
     
No menstrual 
migraine 
Non-menstrual attack 58 34.5 (20) 0.62 (0.14-2.69) 
Menstrual attack   19 31.6 (6) 0.79 (0.12-5.38) 
     
 Triptans    
Menstrual 
migraine 
Non-menstrual attack– ref  191 41.9 (80) 1 
Menstrual attack  167 40.7 (68) 1.32 (0.51-3.44) 
     
No menstrual 
migraine 
Non-menstrual attack  58 8.6 (5) 0.12 (0.01-1.74) 
Menstrual attack   19 10.5 (2) 0.24 (0.01-6.20) 
     
 Multiple-agents    
Menstrual 
migraine 
Non-menstrual attack– ref  191 31.4 (60) 1 
Menstrual attack  167 41.9 (70) 2.10 (1.05-4.23)* 
     
No menstrual 
migraine 
Non-menstrual attack 58 20.7 (12) 0.71 (0.17-2.94) 
Menstrual attack   19 26.3 (5) 1.30 (0.21-8.21) 
     
Diagnosis Continuous variables2 
 
n mean (SD) Coefficient (99% CI) 
 Number of doses per attack    
Menstrual 
migraine 
Non-menstrual attack– ref  189 2.34 (2.68) 0 
Menstrual attack  167 3.62 (4.32 1.37 (0.50-2.24)* 
     
No menstrual 
migraine 
Non-menstrual attack  57 2.14 (2.97) 0.16 (-1.61-1.93) 
Menstrual attack   19 2.05 (3.41) 0.02 (-2.31-2.36) 
1 Linear mixed model with random intercept (SAS MIXED). 2 Logistic regression for hierarchical data with 
random intercept (SAS GLIMMIX). *p<0.01. n=number of attacks without missing values. SD= standard 
deviation. OR= odds ratio. CI=confidence interval. NSAIDs: non-steroidal anti-inflammatory drugs. Multiple 
agents: combination of two or more types of drug (e.g. Triptans and NSAIDs).  
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